Primary Drug |
Interacting Agent |
Effect on Primary and/or Concomitant Drug Concentrations |
Recommendations |
---|---|---|---|
Artemether/ |
Clarithromycin |
↑ lumefantrine expected |
Coadministration should be avoided, if possible. Consider azithromycin in place of clarithromycin. |
Erythromycin |
↑ lumefantrine possible |
Do not coadminister. Consider azithromycin in place of erythromycin. |
|
Fluconazole |
↑ lumefantrine possible |
Coadministration should be avoided, if possible. If coadministered, monitor for lumefantrine toxicities. |
|
Isavuconazole |
↑ lumefantrine possible |
Coadministration should be avoided, if possible. If coadministered, monitor for lumefantrine toxicities. |
|
Itraconazole |
↑ lumefantrine expected |
Coadministration should be avoided, if possible. If coadministered, monitor for lumefantrine toxicities. |
|
Mefloquine |
↓ lumefantrine possible |
If mefloquine is administered immediately before artemether/lumefantrine, monitor for decreased efficacy of artemether/lumefantrine and encourage food intake. |
|
Posaconazole |
↑ lumefantrine expected |
Coadministration should be avoided, if possible. If coadministered, monitor for lumefantrine toxicities. |
|
Rifabutina |
↓ artemether, DHA, and lumefantrine expected |
Use with caution. Monitor for antimalarial efficacy. |
|
Rifampina |
Artemether AUC ↓ 89% DHA AUC ↓ 85% Lumefantrine AUC ↓ 68% |
Do not coadminister. |
|
Rifapentinea |
↓ artemether, DHA, and lumefantrine expected |
Do not coadminister. |
|
Voriconazole |
↑ lumefantrine expected |
Coadministration should be avoided, if possible. If coadministered, monitor for lumefantrine toxicities. |
|
Atovaquone* |
Doxycycline |
Atovaquone concentration ↓ approximately equal to 40% with tetracycline No interaction study with doxycycline |
Dose adjustment not established; if coadministered, instruct patient to take atovaquone with fatty meal and monitor for decreased atovaquone efficacy. |
Rifabutina |
Atovaquone Css ↓ 34% Rifabutin Css ↓ 19% |
Dose adjustment not established; if coadministered, instruct patient to take atovaquone with fatty meal and monitor for decreased atovaquone efficacy. |
|
Rifampina |
Atovaquone Css ↓ 52% Rifampin Css ↑ 37% |
Do not coadminister. |
|
Rifapentinea |
↓ atovaquone expected |
Do not coadminister. |
|
Bedaquiline* |
Clarithromycin |
↑ bedaquiline expected |
Do not coadminister. Consider azithromycin in place of clarithromycin. |
Erythromycin |
↑ bedaquiline possible |
Do not coadminister. Consider azithromycin in place of erythromycin. |
|
Fluconazole |
↑ bedaquiline possible |
Coadministration should be avoided, if possible. If coadministered, monitor for bedaquiline toxicities. |
|
Isavuconazole |
↑ bedaquiline possible |
Coadministration should be avoided, if possible. If coadministered, monitor for bedaquiline toxicities. |
|
Itraconazole |
↑ bedaquiline expected |
Coadministration should be avoided, if possible. If coadministered, monitor for bedaquiline toxicities. If coadministration is required for >14 days, weigh the benefits of therapy against the risks of bedaquiline toxicities. |
|
Posaconazole |
↑ bedaquiline expected |
Coadministration should be avoided, if possible. If coadministered, monitor for bedaquiline toxicities. |
|
Rifabutina |
↔ bedaquiline ↓ rifabutin possible |
If coadministered, separate time of administration; perform rifabutin TDM and adjust dose accordingly. |
|
Rifampina |
Bedaquiline AUC ↓ 53% |
Do not coadminister. |
|
Rifapentinea |
Bedaquiline AUC ↓ 55% (with daily rifapentine) |
Do not coadminister. |
|
Voriconazole |
↑ bedaquiline expected |
Coadministration should be avoided, if possible. If coadministered, monitor for bedaquiline toxicities. |
|
Caspofungin |
Rifabutina |
↓ caspofungin possible |
Monitor for antifungal efficacy. Dose not established. Consider increasing caspofungin dose to 70 mg/day or switch to another echinocandin (e.g., micafungin or anidulafungin). |
Rifampina |
Caspofungin Cmin ↓ 30% |
If coadministered, caspofungin dose should be increased to 70 mg/day. Consider alternative echinocandin (e.g., micafungin or anidulafungin). |
|
Rifapentinea |
Daily Rifapentine
Weekly Rifapentine
|
Monitor for antifungal efficacy. Dose not established. Consider increasing caspofungin dose to 70 mg/day or switch to another echinocandin (e.g., micafungin or anidulafungin). |
|
Chloroquine* | Clarithromycin |
↑ chloroquine expected |
Do not coadminister. Consider azithromycin in place of clarithromycin. |
Erythromycin |
↑ chloroquine possible |
Do not coadminister. Consider azithromycin in place of erythromycin. |
|
Fluconazole |
↑ chloroquine possible |
Coadministration should be avoided, if possible. If coadministered, monitor for chloroquine toxicities. |
|
Isavuconazole |
↑ chloroquine possible |
Coadministration should be avoided, if possible. If coadministered, monitor for chloroquine toxicities. |
|
Itraconazole |
↑ chloroquine expected |
Coadministration should be avoided, if possible. If coadministered, monitor for chloroquine toxicities. |
|
Posaconazole |
↑ chloroquine expected |
Coadministration should be avoided, if possible. If coadministered, monitor for chloroquine toxicities. |
|
Rifabutina |
↓ chloroquine expected |
Monitor for chloroquine efficacy. |
|
Rifampina |
↓ chloroquine expected |
Monitor for chloroquine efficacy. |
|
Rifapentinea |
↓ chloroquine expected |
Monitor for chloroquine efficacy. |
|
Voriconazole |
↑ chloroquine expected |
Coadministration should be avoided, if possible. If coadministered, monitor for chloroquine toxicities. |
|
Clarithromycin* |
Artemether/Lumefantrine |
See Artemether/Lumefantrine. |
See Artemether/Lumefantrine. |
Bedaquiline |
See Bedaquiline. |
See Bedaquiline. |
|
Chloroquine |
See Chloroquine. |
See Chloroquine. |
|
Fluconazole |
Clarithromycin AUC ↑ 18% and Cmin↑ 33% |
No dose adjustment necessary in patients with normal renal function. Monitor for clarithromycin toxicity. |
|
Isavuconazole |
↑ isavuconazole and clarithromycin expected |
Coadministration should be avoided, if possible. Consider azithromycin in place of clarithromycin. If coadministered, monitor for toxicities of both isavuconazole and clarithromycin. Role of isavuconazole TDM has not been established. |
|
Itraconazole |
↑ itraconazole and clarithromycin expected |
Coadministration should be avoided, if possible. Consider azithromycin in place of clarithromycin. If coadministered, monitor for toxicities of both itraconazole and clarithromycin; perform itraconazole and clarithromycin TDM and adjust dose accordingly. |
|
Mefloquine |
↑ mefloquine expected |
Use with caution. Consider azithromycin in place of clarithromycin. If coadministered, monitor for mefloquine toxicity. |
|
Posaconazole |
↑ clarithromycin expected |
Coadministration should be avoided, if possible. Consider azithromycin in place of clarithromycin. If coadministered, monitor for toxicities of clarithromycin; perform clarithromycin TDM and adjust dose accordingly. |
|
Quinine |
↑ quinine expected ↑ clarithromycin possible |
Do not coadminister. Consider azithromycin in place of clarithromycin. |
|
Rifabutina |
Clarithromycin AUC ↓ 44% 14-OH AUC ↑ 57% Rifabutin AUC ↑ 76% to 99% des-Rbt AUC ↑ 375% |
Use with caution. Consider azithromycin in place of clarithromycin. If coadministered, consider reducing rifabutin dose, perform clarithromycin and rifabutin TDM and adjust dose accordingly. Monitor for rifabutin toxicities. |
|
Rifampina |
Clarithromycin concentration ↓ 87% Rifampin AUC ↑ 60% |
Do not coadminister. Use azithromycin in place of clarithromycin. |
|
Rifapentinea |
↓ clarithromycin expected ↑ 14-OH and rifapentine expected |
Daily Rifapentine
Weekly Rifapentine
If coadministered, monitor for rifapentine toxicities and clarithromycin efficacy; perform clarithromycin and rifapentine TDM and adjust doses accordingly. |
|
Voriconazole |
↑ clarithromycin expected |
Coadministration should be avoided, if possible. Consider azithromycin in place of clarithromycin. If coadministered, monitor for toxicities of clarithromycin; perform clarithromycin TDM and adjust dose accordingly. |
|
Dapsone* |
Rifabutina |
Dapsone AUC ↓ 27% to 40% |
Coadministration should be avoided, if possible. Consider alternatives for dapsone. |
Rifampina |
Dapsone concentration ↓ 7-fold to 10-fold and t1/2 ↓ from 24 hours to 11 hours |
Coadministration should be avoided, if possible. Consider alternatives for dapsone. |
|
Rifapentinea |
↓ dapsone expected |
Coadministration should be avoided, if possible. Consider alternatives for dapsone. |
|
Doxycycline |
Atovaquone |
See Atovaquone. |
See Atovaquone. |
Rifabutina |
↓ doxycycline possible |
Monitor closely for doxycycline efficacy or consider alternative therapy. |
|
Rifampina |
Doxycycline AUC ↓ 59% |
Use with caution. Monitor closely for doxycycline efficacy or consider alternative therapy. |
|
Rifapentinea |
Daily Rifapentine
Weekly Rifapentine
|
Use with caution. Monitor closely for doxycycline efficacy or consider alternative therapy. |
|
Erythromycin |
Artemether/Lumefantrine |
See Artemether/Lumefantrine. |
See Artemether/Lumefantrine. |
Bedaquiline |
See Bedaquiline. |
See Bedaquiline. |
|
Chloroquine |
See Chloroquine. |
See Chloroquine. |
|
Fluconazole |
↑ erythromycin possible |
Do not coadminister. Consider azithromycin in place of erythromycin. |
|
Isavuconazole |
↑ erythromycin and isavuconazole possible |
Do not coadminister. Consider azithromycin in place of erythromycin. |
|
Itraconazole |
Itraconazole AUC ↑ 36% ↑ erythromycin possible |
Do not coadminister. Consider azithromycin in place of erythromycin. |
|
Mefloquine |
↑ mefloquine possible |
Do not coadminister. Consider azithromycin in place of erythromycin. |
|
Posaconazole |
↑ erythromycin expected |
Do not coadminister. Consider azithromycin in place of erythromycin. |
|
Quinine |
↑ quinine expected ↑ erythromycin possible |
Do not coadminister. Consider azithromycin in place of erythromycin. |
|
Rifabutina |
↓ erythromycin possible ↑ rifabutin possible |
Use with caution. Consider azithromycin in place of erythromycin. If coadministered, monitor for erythromycin efficacy and rifabutin toxicities; perform rifabutin TDM and adjust dose accordingly. |
|
Rifampina |
↓ erythromycin expected |
Consider azithromycin in place of erythromycin. If coadministered, monitor for erythromycin efficacy. |
|
Rifapentinea |
↓ erythromycin expected |
Consider azithromycin in place of erythromycin. If coadministered, monitor for erythromycin efficacy. |
|
Voriconazole |
↑ erythromycin expected |
Do not coadminister. Consider azithromycin in place of erythromycin. |
|
Fluconazole* |
Artemether/Lumefantrine |
See Artemether/Lumefantrine. |
See Artemether/Lumefantrine. |
Bedaquiline |
See Bedaquiline. |
See Bedaquiline. |
|
Chloroquine |
See Chloroquine. |
See Chloroquine. |
|
Clarithromycin |
See Clarithromycin. |
See Clarithromycin. |
|
Erythromycin |
See Erythromycin. |
See Erythromycin. |
|
Mefloquine |
↑ mefloquine possible |
Coadministration should be avoided, if possible. If coadministered, monitor for mefloquine toxicities. |
|
Quinine |
↑ quinine expected ↑ fluconazole possible |
Coadministration should be avoided, if possible. If coadministered, monitor for quinine and fluconazole toxicity. |
|
Rifabutina |
Rifabutin AUC ↑ 80% ↔ fluconazole |
Use with caution. Monitor for rifabutin toxicities. Perform rifabutin TDM; may need to decrease rifabutin dose to 150 mg/day. |
|
Rifampina |
Fluconazole AUC ↓ 23% to 56% |
Monitor for antifungal efficacy; may need to increase fluconazole dose. |
|
Rifapentinea |
↓ fluconazole expected |
Monitor for antifungal efficacy; may need to increase fluconazole dose. |
|
Glecaprevir/ Pibrentasvir |
Rifabutina |
↓ glecaprevir and pibrentasvir possible |
Coadministration should be avoided, if possible. Consider alternative agents. |
Rifampina |
Glecaprevir AUC ↓ 88% Pibrentasvir AUC ↓ 87% |
Do not coadminister. |
|
Rifapentinea |
↓ glecaprevir and pibrentasvir expected |
Do not coadminister. Consider alternative agents. |
|
TDF |
TFV AUC ↑ 29% when coadministered as EFV/TDF/FTC |
Use usual dose. Monitor renal function or consider TAF. |
|
TAF |
↔ TFV concentration when coadministered as EVG/c/TAF/FTC |
No dose adjustment |
|
Isavuconazole* |
Artemether/Lumefantrine |
See Artemether/Lumefantrine. |
See Artemether/Lumefantrine. |
Bedaquiline |
See Bedaquiline. |
See Bedaquiline. |
|
Chloroquine |
See Chloroquine. |
See Chloroquine. |
|
Clarithromycin |
See Clarithromycin. |
See Clarithromycin. |
|
Erythromycin |
See Erythromycin. |
See Erythromycin. |
|
Mefloquine |
↑ mefloquine expected |
Coadministration should be avoided, if possible. If coadministered, monitor for mefloquine toxicities. |
|
Quinine |
↑ quinine expected ↑ isavuconazole possible |
Coadministration should be avoided, if possible. If coadministered, monitor for quinine and isavuconazole toxicities. |
|
Rifabutina |
↓ isavuconazole expected ↑ rifabutin expected |
Consider alternative agent(s). If alternative agents are not available, use with close monitoring for isavuconazole antifungal activity and rifabutin toxicity. Perform rifabutin TDM and adjust dose accordingly. |
|
Rifampina |
Isavuconazole AUC ↓ 97% |
Do not coadminister. Consider alternative antifungal and/or antimycobacterial agent(s). |
|
Rifapentinea |
Significant ↓ isavuconazole expected |
Do not coadminister. Consider alternative antifungal and/or antimycobacterial agent(s). |
|
Itraconazole* |
Artemether/Lumefantrine |
See Artemether/Lumefantrine. |
See Artemether/Lumefantrine. |
Bedaquiline |
See Bedaquiline. |
See Bedaquiline. |
|
Chloroquine |
See Chloroquine. |
See Chloroquine. |
|
Clarithromycin |
See Clarithromycin. |
See Clarithromycin. |
|
Erythromycin |
See Erythromycin. |
See Erythromycin. |
|
Mefloquine |
↑ mefloquine expected |
Coadministration should be avoided, if possible. If coadministered, monitor for mefloquine toxicities. |
|
Quinine |
↑ quinine expected ↑ itraconazole possible |
Coadministration should be avoided, if possible. If coadministered, monitor for quinine and itraconazole toxicities; perform itraconazole TDM and adjust dose accordingly. |
|
Rifabutina |
Itraconazole AUC ↓ 70% ↑ rifabutin expected |
Do not coadminister. Consider alternative antifungal and/or antimycobacterial agent(s). |
|
Rifampina |
Itraconazole AUC ↓ 64% to 88% |
Do not coadminister. Consider alternative antifungal and/or antimycobacterial agent(s). |
|
Rifapentinea |
↓ itraconazole expected |
Do not coadminister. Consider alternative antifungal and/or antimycobacterial agent(s). |
|
Linezolid* |
Rifabutina |
↓ linezolid possible |
Monitor for linezolid efficacy. |
Rifampina |
Linezolid AUC ↓ 32% |
Monitor for linezolid efficacy. Perform linezolid TDM and adjust dose accordingly. |
|
Rifapentinea |
Daily Rifapentine
Weekly Rifapentine
|
Daily rifapentine
Weekly rifapentine
|
|
Mefloquine* |
Artemether/Lumefantrine |
See Artemether/Lumefantrine. |
See Artemether/Lumefantrine. |
Clarithromycin |
See Clarithromycin. |
See Clarithromycin. |
|
Erythromycin |
See Erythromycin. |
See Erythromycin. |
|
Fluconazole |
See Fluconazole. |
See Fluconazole. |
|
Isavuconazole |
See Isavuconazole. |
See Isavuconazole. |
|
Itraconazole |
See Itraconazole. |
See Itraconazole. |
|
Posaconazole |
↑ mefloquine expected |
Coadministration should be avoided, if possible. If coadministered, monitor for mefloquine toxicities. |
|
Rifabutina |
↓ mefloquine possible |
Monitor for mefloquine efficacy. |
|
Rifampina |
Mefloquine AUC ↓ 68% |
Do not coadminister. Use alternative antimalarial drug or rifabutin. |
|
Rifapentinea |
↓ mefloquine expected |
Do not coadminister. Use alternative antimalarial drug or rifabutin. |
|
Voriconazole |
↑ mefloquine expected |
Coadministration should be avoided, if possible. If coadministered, monitor for mefloquine toxicities. |
|
Posaconazole* |
Artemether/Lumefantrine |
See Artemether/Lumefantrine. |
See Artemether/Lumefantrine. |
Bedaquiline |
See Bedaquiline. |
See Bedaquiline. |
|
Chloroquine |
See Chloroquine. |
See Chloroquine. |
|
Clarithromycin |
See Clarithromycin. |
See Clarithromycin. |
|
Erythromycin |
See Erythromycin. |
See Erythromycin. |
|
Mefloquine |
See Mefloquine. |
See Mefloquine. |
|
Quinine |
↑ quinine expected ↑ posaconazole possible |
Coadministration should be avoided, if possible. If coadministered, monitor for quinine toxicities. |
|
Rifabutina |
Posaconazole AUC ↓ 49% Rifabutin AUC ↑ 72% |
Coadministration should be avoided, if possible. If coadministered, perform posaconazole and rifabutin TDM and adjust doses accordingly; monitor for clinical response to posaconazole and rifabutin toxicities. |
|
Rifampina |
Significant ↓ posaconazole expected |
Do not coadminister when treating invasive fungal infections. If coadministered for treatment of non-invasive fungal infections, perform posaconazole TDM and adjust dose accordingly; monitor for clinical response. |
|
Rifapentinea |
↓ posaconazole expected |
Daily Rifapentine
Weekly Rifapentine
|
|
Quinine* |
Clarithromycin |
See Clarithromycin. |
See Clarithromycin. |
Erythromycin |
See Erythromycin. |
See Erythromycin. |
|
Fluconazole |
See Fluconazole. |
See Fluconazole. |
|
Itraconazole |
See Itraconazole. |
See Itraconazole. |
|
Posaconazole |
See Posaconazole. |
See Posaconazole. |
|
Rifabutina |
↓ quinine possible ↑ rifabutin possible |
Monitor for quinine efficacy. Monitor for rifabutin toxicity. |
|
Rifampina |
Quinine AUC ↓ 75% to 85% |
Do not coadminister. |
|
Rifapentinea |
↓ quinine expected |
Do not coadminister. |
|
Voriconazole |
↑ quinine expected |
Coadministration should be avoided, if possible. If coadministered, monitor for quinine toxicities. |
|
Rifabutina* |
Artemether/Lumefantrine |
See Artemether/Lumefantrine. |
See Artemether/Lumefantrine. |
Atovaquone |
See Atovaquone. |
See Atovaquone. |
|
Bedaquiline |
See Bedaquiline. |
See Bedaquiline. |
|
Caspofungin |
See Caspofungin. |
See Caspofungin. |
|
Chloroquine |
See Chloroquine. |
See Chloroquine. |
|
Clarithromycin |
See Clarithromycin. |
See Clarithromycin. |
|
Dapsone |
See Dapsone. |
See Dapsone. |
|
Doxycycline |
See Doxycycline. |
See Doxycycline. |
|
Erythromycin |
See Erythromycin. |
See Erythromycin. |
|
Fluconazole |
See Fluconazole. |
See Fluconazole. |
|
Glecaprevir/Pibrentasvir |
See Glecaprevir/Pibrentasvir. |
See Glecaprevir/Pibrentasvir. |
|
Isavuconazole |
See Isavuconazole. |
See Isavuconazole. |
|
Itraconazole |
See Itraconazole. |
See Itraconazole. |
|
Linezolid |
See Linezolid. |
See Linezolid. |
|
Mefloquine |
See Mefloquine. |
See Mefloquine. |
|
Posaconazole |
See Posaconazole. |
See Posaconazole. |
|
Quinine |
See Quinine. |
See Quinine. |
|
Sofosbuvir/Velpatasvir |
↓ velpatasvir, sofosbuvir expected |
Do not coadminister. |
|
TAF |
↓ TAF, TFV, TFV-DP expected ↑ TFV-DP expected versus TDF alone |
If coadministered, monitor for HIV and HBV treatment efficacy. Note: Interpretation extrapolated from TAF and rifampin (see Rifampin). FDA labeling recommends not to coadminister. |
|
TDF |
↔ TDF, TFV, TFV-DP expected |
No dosage adjustment necessary. |
|
Voriconazole |
Voriconazole AUC ↓ 79% Rifabutin AUC ↑ 4-fold |
Do not coadminister. Consider alternative antifungal and/or antimycobacterial agent(s). Coadministration may be considered if both voriconazole and rifabutin TDM is available to guide therapy. |
|
Rifampina* |
Artemether/Lumefantrine |
See Artemether/Lumefantrine. |
See Artemether/Lumefantrine. |
Atovaquone |
See Atovaquone. |
See Atovaquone. |
|
Bedaquiline |
See Bedaquiline. |
See Bedaquiline. |
|
Caspofungin |
See Caspofungin. |
See Caspofungin. |
|
Chloroquine |
See Chloroquine. |
See Chloroquine. |
|
Clarithromycin |
See Clarithromycin. |
See Clarithromycin. |
|
Dapsone |
See Dapsone. |
See Dapsone. |
|
Doxycycline |
See Doxycycline. |
See Doxycycline. |
|
Erythromycin |
See Erythromycin. |
See Erythromycin. |
|
Fluconazole |
See Fluconazole. |
See Fluconazole. |
|
Glecaprevir/Pibrentasvir |
See Glecaprevir/Pibrentasvir. |
See Glecaprevir/Pibrentasvir. |
|
Isavuconazole |
See Isavuconazole. |
See Isavuconazole. |
|
Itraconazole |
See Itraconazole. |
See Itraconazole. |
|
Linezolid |
See Linezolid. |
See Linezolid. |
|
Mefloquine |
See Mefloquine. |
See Mefloquine. |
|
Posaconazole |
See Posaconazole. |
See Posaconazole. |
|
Quinine |
See Quinine. |
See Quinine. |
|
Sofosbuvir/Velpatasvir |
Sofosbuvir AUC ↓ 72% Velpatasvir AUC ↓ 82% |
Do not coadminister. |
|
TAF |
TAF plus Rifampin
Intracellular TFV-DP concentration is 4.2-fold greater than with TDF alone. |
If coadministered, monitor for HIV and HBV treatment efficacy. Note: FDA labeling recommends not to coadminister. |
|
TDF |
TDF plus Rifampin 600 mg Daily
|
No dosage adjustment necessary |
|
Voriconazole |
Voriconazole AUC ↓96% |
Do not coadminister. Consider alternative antifungal and/or antimycobacterial agent(s). |
|
Rifapentinea* |
Artemether/Lumefantrine |
See Artemether/Lumefantrine. |
See Artemether/Lumefantrine. |
Atovaquone |
See Atovaquone. |
See Atovaquone. |
|
Bedaquiline |
See Bedaquiline. |
See Bedaquiline. |
|
Caspofungin |
See Caspofungin. |
See Caspofungin. |
|
Chloroquine |
See Chloroquine. |
See Chloroquine. |
|
Clarithromycin |
See Clarithromycin. |
See Clarithromycin. |
|
Dapsone |
See Dapsone. |
See Dapsone. |
|
Doxycycline |
See Doxycycline. |
See Doxycycline. |
|
Erythromycin |
See Erythromycin. |
See Erythromycin. |
|
Fluconazole |
See Fluconazole. |
See Fluconazole. |
|
Glecaprevir/Pibrentasvir |
See Glecaprevir/Pibrentasvir. |
See Glecaprevir/Pibrentasvir. |
|
Isavuconazole |
See Isavuconazole. |
See Isavuconazole. |
|
Itraconazole |
See Itraconazole. |
See Itraconazole. |
|
Linezolid |
See Linezolid. |
See Linezolid. |
|
Mefloquine |
See Mefloquine. |
See Mefloquine. |
|
Posaconazole |
See Posaconazole. |
See Posaconazole. |
|
Quinine |
See Quinine. |
See Quinine. |
|
TAF |
Daily Rifapentine
Weekly Rifapentine
|
Daily Rifapentine
Weekly Rifapentine If coadministered, monitor for HIV and HBV treatment efficacy. Note: FDA labeling recommends not to coadminister. |
|
TDF |
↔ TDF, TFV, TFV-DP expected |
No dosage adjustment necessary. |
|
Sofosbuvir/Velpatasvir |
↓ sofosbuvir, velpatasvir expected |
Do not coadminister. |
|
Voriconazole |
↓ voriconazole expected |
Do not coadminister. Consider alternative antifungal and/or antimycobacterial agent(s). |
|
Sofosbuvir*/ Velpatasvir |
Rifabutina |
See Rifabutin. |
See Rifabutin. |
Rifampina |
See Rifampin. |
See Rifampin. |
|
Rifapentinea |
See Rifapentine. |
See Rifapentine. |
|
TAF |
TFV AUC ↑ 52% (when RPV/TAF/FTC given with SOF/VEL/VOX) |
No dosage adjustment. |
|
TDF |
TFV AUC ↑ 35% to 40% (when given with EVG/c/FTC or RPV/FTC) TFV AUC ↑ 81% (when given with EFV/FTC and SOF/VEL) TFV AUC ↑ 39% (when given with DRV/r/FTC and SOF/VEL/VOX) |
Monitor for TDF toxicities. Consider TAF in place of TDF. |
|
Tenofovir* Alafenamide |
Glecaprevir/Pibrentasvir |
See Glecaprevir/Pibrentasvir. |
See Glecaprevir/Pibrentasvir. |
Rifabutina |
See Rifabutin. |
See Rifabutin. |
|
Rifampina |
See Rifampin. |
See Rifampin. |
|
Rifapentinea |
See Rifapentine. |
See Rifapentine. |
|
Sofosbuvir/Velpatasvir |
See Sofosbuvir/Velpatasvir. |
See Sofosbuvir/Velpatasvir. |
|
Tenofovir* Disoproxil Fumarate |
Rifabutina |
See Rifabutin. |
See Rifabutin. |
Rifampina |
See Rifampin. |
See Rifampin. |
|
Rifapentinea |
See Rifapentine. |
See Rifapentine. |
|
Glecaprevir/Pibrentasvir |
See Glecaprevir/Pibrentasvir. |
See Glecaprevir/Pibrentasvir. |
|
Sofosbuvir/Velpatasvir |
See Sofosbuvir/Velpatasvir. |
See Sofosbuvir/Velpatasvir. |
|
Voriconazole* |
Artemether/Lumefantrine |
See Artemether/Lumefantrine. |
See Artemether/Lumefantrine. |
Bedaquiline |
See Bedaquiline. |
See Bedaquiline. |
|
Chloroquine |
See Chloroquine. |
See Chloroquine. |
|
Clarithromycin |
See Clarithromycin. |
See Clarithromycin. |
|
Erythromycin |
See Erythromycin. |
See Erythromycin. |
|
Mefloquine |
See Mefloquine. |
See Mefloquine. |
|
Quinine |
See Quinine. |
See Quinine. |
|
Rifabutina |
See Rifabutin. |
See Rifabutin. |
|
Rifampina |
See Rifampin. |
See Rifampin. |
|
Rifapentinea |
See Rifapentine. |
See Rifapentine. |
|
aRefer to the description of Rifamycin-Related Induction Interactions in the Table 4 introduction above. * Drug names marked with asterisk (*) are known to have assays available in the United States and, typically, in Europe as well. Key to Symbols ↑ = increase ↓ = decrease ↔ = no substantial change Key: 14-OH = active metabolite of clarithromycin; AUC = area under the curve; Cmin = minimum concentration; Css = concentration at steady state; des-Rbt = desacetyl rifabutin; DHA = dihydroartemisinin; DRV/r = darunavir/ritonavir; EFV = efavirenz; EVG/c = elvitegravir/cobicistat; FDA = U.S. Food and Drug Administration; FTC = emtricitabine; HBV = hepatitis B virus; RPV = rilpivirine; SOF = sofosbuvir; t1/2 = half-life; TAF = tenofovir alafenamide; TDF = tenofovir disoproxil fumarate; TDM = therapeutic drug monitoring; TFV= tenofovir; TFV-DP = tenofovir diphosphate; VEL = velpatasvir; VOX = voxilaprevir |